GLP-1 medicines show potential kidney benefits in specific patient groups

Recent research and clinical analysis suggest that GLP-1 receptor agonists, commonly used for weight management and type 2 diabetes, may offer significant kidney protection. A study published in The Journal of Clinical Psychiatry, conducted by Mayo Clinic researchers using an international health database, found that adults with bipolar disorder and chronic kidney disease who used GLP-1 medicines had lower observed rates of dialysis or kidney transplantation compared to those using DPP-4 inhibitors or RAAS-affecting medicines.

In the matched DPP-4 comparison, approximately 87.93% of GLP-1 users remained free of dialysis or kidney transplantation at five years, compared to 84.63% in the comparison group. In the RAAS comparison, the rates were 94.68% for GLP-1 users versus 89.77% for the comparison group.

While semaglutide has shown a 24% reduction in composite endpoints for patients with type 2 diabetes and chronic kidney disease, experts caution that GLP-1 agonists and SGLT2 inhibitors should be viewed as complementary rather than interchangeable. SGLT2 inhibitors have established kidney protection benefits, such as the 39% relative reduction seen in the DAPA-CKD trial. Clinical experts emphasize that treatment decisions should focus on a patient's specific overlapping conditions rather than formulary economics or drug class substitution.